On October 22, 2021, Grandway Biotechnology (01548.HK) announced that on October 22, 2021, the Company's non-wholly-owned subsidiary, Kingsway Biotechnology, entered into a general service agreement with Suzhou Abbott Biotechnology Co., Ltd. ("Abbott") and Yuxi Watson Biotechnology Co., Ltd. ("Watson") for the biological product licensing application ("BLA") of the mRNA vaccine and its commercial production. Watson will become the main applicant for the project, and Jinsrui Vigorous Bio will become the exclusive service provider for the commercial production of the project plasmid.
According to the disclosure, in June 2020, the COVID-19 mRNA vaccine jointly developed by Abbott, Watson and a Chinese medical institution has been approved by the State Drug Administration ("NMPA") for clinical trials, which is the first batch of mRNA vaccine projects in the country. With its Good Manufacturing Practice (GMP) plasmid production platform and multiple clinical plasmid production experience, Jinsrui Vigorous Biotech quickly moved the project into clinical trials. As of the date of the announcement, phase III clinical trials of the project have been approved by the drug regulatory authorities of Mexico, Indonesia and Nepal. Watson's modular facility was commissioned in September 2021 for the commercial production of a COVID-19 mRNA vaccine. The Group believes that after the signing of the service agreement, all parties will give full play to their respective advantages and cooperate to promote the commercialization of the COVID-19 mRNA vaccine and contribute to the prevention and control of the epidemic.
This article originated from Grand Gateway
![Explosive melon, the richest man quietly built a warehouse Watson creature, pay close attention to the melon of the possible more preemptive Watson creatures a brain hole[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)